指南与共识其他结缔组织病

2016年ACR-EULAR肌炎反应标准在幼年皮肌炎治疗试验与共识病例中的表现

Performance of the 2016 ACR-EULAR myositis response criteria in juvenile dermatomyositis therapeutic trials and consensus profiles.
指南 / 共识 · Rheumatology (Oxford) · 2023-01-01

研究评估2016年ACR-EULAR幼年皮肌炎反应标准的验证表现,纳入利妥昔单抗试验48例、PRINTO试验139例及共识病例273例。结果显示不同研究中反应标准表现一致,医师评估变化与反应类别间具有中等至高度一致性(Kappa 0.5-0.7)。

要点

  • 在457例具有IMACS核心指标的患者中,9-13%为轻微改善,19-23%为中度改善,41-50%为显著改善。
  • 按反应标准改善的患者中,94-95%肌力改善,93-95%有至少1项患者报告指标改善。
  • IMACS与PRINTO核心指标表现相似,医师评估变化与反应类别一致性为中等至高度(Kappa 0.5-0.7)。

核心结论

  • ACR-EULAR肌炎反应标准在多项研究中表现一致,支持其继续作为幼年皮肌炎试验的疗效终点。

研究设计与样本

  • 研究纳入利妥昔单抗治疗肌炎试验中幼年皮肌炎患者48例、PRINTO幼年皮肌炎试验139例及共识患者病例273例,共457例具有IMACS核心指标、380例具有PRINTO核心指标。
  • 采用符号检验比较核心指标观察贡献与预期贡献,Wilcoxon检验(Bonferroni校正)比较反应类别特征,Spearman相关分析总改善评分与各核心指标变化的相关性,加权Cohen kappa评估医师评估变化与反应类别的一致性。

主要发现

  • 457例具有IMACS核心指标的幼年皮肌炎患者中,9-13%为轻微改善,19-23%为中度改善,41-50%为显著改善;380例具有PRINTO核心指标的患者数据类似。
  • 反应标准改善级别越高,改善的核心指标数量和绝对百分比变化越大;轻微改善患者中位恶化核心指标数为0-1个,中度或显著改善患者中位恶化核心指标数为0个。
  • 按反应标准改善的患者中,94-95%肌力改善,93-95%至少1项患者报告核心指标改善;IMACS与PRINTO核心指标表现相似。
  • 医师评估变化与反应标准改善类别的一致性为中等至高度(Kappa 0.5-0.7)。

关键数值与推荐

  • 2016年ACR-EULAR幼年皮肌炎反应标准为复合指标,对6项核心指标给予不同权重以计算总改善评分。
  • 反应标准改善类别:轻微改善9-13%、中度改善19-23%、显著改善41-50%(基于457例具有IMACS核心指标的患者)。

临床怎么用

  • 原文结论支持ACR-EULAR肌炎反应标准作为幼年皮肌炎试验的疗效终点继续使用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The 2016 ACR-EULAR Response Criteria for JDM was developed as a composite measure with differential weights of six core set measures (CSMs) to calculate a Total Improvement Score (TIS). We assessed the contribution of each CSM, representation of muscle-related and patient-reported CSMs towards improvement, and frequency of CSM worsening across myositis response criteria (MRC) categories in validation of MRC. METHODS: Data from JDM patients in the Rituximab in Myositis trial (n = 48), PRINTO JDM trial (n = 139), and consensus patient profiles (n = 273) were included. Observed vs expected CSM contributions were compared using Sign test. Characteristics of MRC categories were compared by Wilcoxon tests with Bonferroni adjustment. Spearman correlation of changes in TIS and individual CSMs were examined. Agreement between physician-assessed change and MRC categories was evaluated by weighted Cohen's kappa. RESULTS: Of 457 JDM patients with IMACS CSMs and 380 with PRINTO CSMs, 9-13% had minimal, 19-23% had moderate and 41-50% had major improvement. The number of improved and absolute percentage change of CSMs increased by MRC improvement level. Patients with minimal improvement by MRC had a median of 0-1 CSM worsened, and those with moderate/major improvement had a median of zero worsening CSMs. Of patients improved by MRC, 94-95% had improvement in muscle strength and 93-95% had improvement in ≥1 patient-reported CSM. IMACS and PRINTO CSMs performed similarly. Physician-rated change and MRC improvement categories had moderate-to-substantial agreement (Kappa 0.5-0.7). CONCLUSION: The ACR-EULAR MRC perform consistently across multiple studies, supporting its further use as an efficacy end point in JDM trials.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Kim H, Saygin D, Douglas C, et al. Performance of the 2016 ACR-EULAR myositis response criteria in juvenile dermatomyositis therapeutic trials and consensus profiles. Rheumatology (Oxford). 2023. PMID: 36929918. doi:10.1093/rheumatology/kead111

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。